{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:28:36Z","timestamp":1786609716623,"version":"build-2736575974"},"reference-count":255,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Cancer immunotherapy has transformed the global oncology landscape, offering durable responses across malignancies once considered untreatable. In Asia and Southeast Asia, regions facing a rising cancer burden, countries such as Malaysia are progressively integrating immunotherapeutic approaches, including immune checkpoint inhibitors and CAR-T cell therapies. Regional progress is supported by investments in research infrastructure, expanding clinical trial participation, and cross-border regulatory collaboration. However, significant challenges persist. Diverse genetic and epidemiological profiles complicate treatment generalizability, while disparities in healthcare access, limited biomarker validation, and high costs restrict widespread implementation, particularly in low- and middle-income settings. In Southeast Asia, including Malaysia, these challenges are intensified by urban-rural disparities in healthcare access and financial limitations. However, emerging opportunities such as biomarker-informed precision immunotherapy, artificial intelligence-enabled treatment personalization, expanded telemedicine services, and enhanced access frameworks offer promising pathways forward. This review highlights the current landscape, ongoing challenges, and future prospects of cancer immunotherapy in Asia and Southeast Asia, with a particular focus on Malaysia\u2019s growing role in this evolving field. Cross-regional cooperation, regulatory harmonization, and personalized treatment strategies are crucial for equitable access to cancer therapies across this region. By synthesizing fragmented and underrepresented evidence from Southeast Asia within a broader Asia-focused immunotherapy framework, this review aims to provide a consolidated reference that can guide future research prioritization, strengthen regional policy development, and support the design of more inclusive and scalable immunotherapy implementation strategies.<\/jats:p>","DOI":"10.3389\/fonc.2026.1847284","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:43:29Z","timestamp":1786607009000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy in Asia: current insights and prospects in Southeast Asia and Malaysia"],"prefix":"10.3389","volume":"16","author":[{"given":"Ros Suzanna Ahmad","family":"Bustamam","sequence":"first","affiliation":[{"name":"Department of Radiotherapy and Oncology, Hospital Kuala Lumpur","place":["Kuala Lumpur, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee Peng","family":"Phoon","sequence":"additional","affiliation":[{"name":"Center for Immunotherapy & Precision Immuno-Oncology, Department of Cancer Sciences, Cleveland Clinic","place":["Cleveland, OH, United States"]},{"name":"School of Medicine, Case Western Reserve University","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00017-8","article-title":"Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis","volume":"26","author":"Dee","year":"2025","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100971","article-title":"Cancer disparities in Southeast Asia: intersectionality and a call to action","volume":"41","author":"Feliciano","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"B4","article-title":"Malaysia national cancer registry report (MNCR) 2017-2021","author":"Mohd Anis","year":"2025","journal-title":"MNCR"},{"key":"B5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02272","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/nejmoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)\/HER2(-) breast cancer: a randomized phase 3 trial","volume":"31","author":"Cardoso","year":"2025","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001282","article-title":"Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer","volume":"8","author":"Reuss","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-2994","article-title":"Five-year clinical outcomes after neoadjuvant nivolumab in resectable non-small cell lung cancer","volume":"29","author":"Rosner","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/nejmoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae129","article-title":"Neoadjuvant pembrolizumab plus chemotherapy\/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study","volume":"116","author":"Dent","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.06.010","article-title":"Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the international association for the study of lung cancer","volume":"19","author":"Spicer","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemoimmunotherapy for NSCLC: A systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s2214-109x(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"de Martel","year":"2020","journal-title":"Lancet Glob Health"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2016.0270","article-title":"Epstein-Barr virus infection and nasopharyngeal carcinoma","volume":"372","author":"Tsao","year":"2017","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/0030-4220(93)90436-8","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61507-3","article-title":"Health and health-care systems in southeast Asia: diversity and transitions","volume":"377","author":"Chongsuvivatwong","year":"2011","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100667","article-title":"Disparities in access to cancer diagnostics in ASEAN member countries","volume":"32","author":"Alberto","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.5194507","article-title":"Can Malaysia tackle the cancer crisis? Addressing the oncologist shortage and shaping healthcare innovations for a healthier future over the next decade","author":"Jack Ng","year":"2025","journal-title":"SSRN"},{"key":"B35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1200\/jco.2015.62.0096","article-title":"Cancer genomics: diversity and disparity across ethnicity and geography","volume":"34","author":"Tan","year":"2016","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003024","article-title":"Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies","volume":"10","author":"Michielin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02336-1","article-title":"Neoadjuvant immunotherapy for melanoma is now ready for clinical practice","volume":"29","author":"Garbe","year":"2023","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.annonc.2023.10.052","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01230-4","article-title":"Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study","volume":"25","author":"Kang","year":"2022","journal-title":"Gastric Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-2439","article-title":"Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma","volume":"24","author":"Huang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B48","article-title":"Immunotherapy for PD-L1 positive advanced non-small cell lung cancer","author":"Emi","year":"2022","journal-title":"Health Technol Assess Rep Malaysian Health Technol Assess Section (MaHTAS)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1781333","article-title":"A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy","volume":"9","author":"Peng","year":"2020","journal-title":"Oncoimmunology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.01.006","article-title":"Nivolumab versus docetaxel in a predominantly chinese patient population with previously treated advanced NSCLC: checkMate 078 randomized phase III clinical trial","volume":"14","author":"Wu","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.lungcan.2020.11.013","article-title":"Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)","volume":"152","author":"Lu","year":"2021","journal-title":"Lung Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33534","article-title":"Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer","volume":"149","author":"Low","year":"2021","journal-title":"Int J Cancer"},{"key":"B53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2024.09.1157","article-title":"EP.11E.04 Low-Dose Nivolumab in Advanced NSCLC; Light at the End of the Tunnel","volume-title":"J. Thorac. Oncol.","author":"Alaga","year":"2024"},{"key":"B54","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1634\/theoncologist.2019-0284","article-title":"A phase I\/II open-label study of nivolumab in previously treated advanced or recurrent nasopharyngeal carcinoma and other solid tumors","volume":"24","author":"Ma","year":"2019","journal-title":"Oncologist"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1186\/s12885-023-11203-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study","volume":"23","author":"Tokito","year":"2024","journal-title":"BMC Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-026-03578-4","article-title":"First-line pembrolizumab plus chemotherapy for advanced biliary tract cancer: China subgroup analysis of the randomized phase 3 KEYNOTE-966 study","author":"Ren","year":"2026","journal-title":"Adv Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-076898","article-title":"Pembrolizumab (MK-3475) plus platinum and gemcitabine as first-line treatment of recurrent\/metastatic head and neck squamous cell carcinoma (PIPER): a phase 2, multicentre, single-arm protocol study in Malaysia","volume":"14","author":"Cheong","year":"2024","journal-title":"BMJ Open"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/go-25-00095","article-title":"Barriers to immune checkpoint inhibitor access for patients with cancer in Southeast Asia: Challenges and policy implications","volume":"11","author":"Go","year":"2025","journal-title":"JCO Glob Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107418","article-title":"Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide","volume":"186","author":"Liu","year":"2023","journal-title":"Lung Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-023-00257-0","article-title":"Long-term survival and stable disease in a patient with extensive-stage small-cell lung cancer after treatment with carboplatin, etoposide and atezolizumab","volume":"12","author":"Bernabe","year":"2024","journal-title":"Oncol Ther"},{"key":"B65","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-025-01768-1","article-title":"PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy","volume":"18","author":"Wu","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejca.2021.12.012","article-title":"Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma","volume":"163","author":"Sonpavde","year":"2022","journal-title":"Eur J Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00892","article-title":"Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: Results from JAVELIN Gastric 100","volume":"39","author":"Moehler","year":"2021","journal-title":"J Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Ann Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.07.005","article-title":"Subgroup analysis of Japanese patients in a phase III study of atezolizumab in extensive-stage small-cell lung cancer (IMpower133)","volume":"20","author":"Nishio","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.lungcan.2023.01.013","article-title":"NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer","volume":"178","author":"Cheng","year":"2023","journal-title":"Lung Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: The MYSTIC phase 3 randomized clinical trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104812","article-title":"The effects of race on anti-PD-(L)1 monoclonal antibodies in non-small cell lung cancer: A systematic literature review and meta-analysis","volume":"214","author":"Genova","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"16753","DOI":"10.1038\/s41598-024-67508-6","article-title":"PD-L1 expression and its correlation with tumor biomarkers in Chinese urothelial bladder cancer","volume":"14","author":"Fan","year":"2024","journal-title":"Sci Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.10.012","article-title":"PD-L1 score as a prognostic biomarker in Asian early-stage epidermal growth factor receptor-mutated lung cancer","volume":"178","author":"Saw","year":"2023","journal-title":"Eur J Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1321813","article-title":"The predictive value of PD-L1 expression in response to anti-PD-1\/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis","volume":"15","author":"Yoon","year":"2024","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-11-1823","article-title":"CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma","volume":"18","author":"Prieto","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000891","article-title":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","volume":"8","author":"Motzer","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Andre","year":"2024","journal-title":"N Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.02.006","article-title":"ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer","volume":"31","author":"Planchard","year":"2020","journal-title":"Ann Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"100394","DOI":"10.1016\/j.esmoop.2022.100394","article-title":"First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients","volume":"7","author":"O'Byrne","year":"2022","journal-title":"ESMO Open"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1038\/s41467-023-38407-7","article-title":"Clinical efficacy and biomarker analysis of dual PD-1\/CTLA-4 blockade in recurrent\/metastatic EBV-associated nasopharyngeal carcinoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat Commun"},{"key":"B84","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.116","article-title":"Cardiovascular toxicity with CTLA-4 inhibitors in cancer patients: A meta-analysis","volume":"3","author":"Liu","year":"2024","journal-title":"Cancer Innov"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1009731107","article-title":"Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection","volume":"107","author":"Jin","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200773","article-title":"Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party","volume":"32","author":"Lu","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40164-023-00421-2","article-title":"Targeting TIM-3 for hematological Malignancy: latest updates from the 2022 ASH annual meeting","volume":"12","author":"Tan","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012729","article-title":"First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and\/or metastatic solid tumors","volume":"14","author":"Rohrberg","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/nejmoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01636","article-title":"First-line nivolumab and relatlimab plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma: The phase II RELATIVITY-060 study","volume":"42","author":"Hegewisch-Becker","year":"2024","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005829","article-title":"AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors","volume":"11","author":"Frentzas","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010584","article-title":"TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial","volume":"13","author":"Naing","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ygyno.2025.04.579","article-title":"AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer","volume":"198","author":"Lee","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B99","first-page":"34S621","article-title":"1020MO AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent\/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity","volume-title":"Ann. Oncol","author":"Wang","year":"2023"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100911","article-title":"AdvanTIG-204: A phase 2, randomized, open-label study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy versus tislelizumab and concurrent chemotherapy versus concurrent chemoradiotherapy in first-line limited-stage SCLC","volume":"6","author":"Gong","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07121-9","article-title":"Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cells","volume":"627","author":"Guan","year":"2024","journal-title":"Nature"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2343272","article-title":"The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced Malignancies","volume":"20","author":"Shapira-Frommer","year":"2024","journal-title":"Future Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01363","article-title":"SKYSCRAPER-02: Tiragolumab in combination with atezolizumab plus chemotherapy in untreated extensive-stage small-cell lung cancer","volume":"42","author":"Rudin","year":"2024","journal-title":"J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-ct051","article-title":"SKYSCRAPER-01: A phase III, randomized trial of tiragolumab (tira) plus atezolizumab (atezo) versus placebo (pbo) plus atezo in patients (pts) with previously untreated PD-L1-high, locally advanced unresectable\/metastatic NSCLC Free","volume":"85","author":"Peters","year":"2025","journal-title":"Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00709-0","article-title":"Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study","volume":"27","author":"Dummer","year":"2026","journal-title":"Lancet Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J Exp Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-024-01336-6","article-title":"VISTA-mediated immune evasion in cancer","volume":"56","author":"Zhang","year":"2024","journal-title":"Exp Mol Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi7418","article-title":"LRIG1 engages ligand VISTA and impairs tumor-specific CD8(+) T cell responses","volume":"9","author":"Ta","year":"2024","journal-title":"Sci Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102942","article-title":"Viewing the immune checkpoint VISTA: landscape and outcomes across cancers","volume":"9","author":"Nishizaki","year":"2024","journal-title":"ESMO Open"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1225081","article-title":"Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights","volume":"13","author":"Noelle","year":"2023","journal-title":"Front Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-sitc2020.0392","article-title":"392 Phase 1 study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor Malignancies","volume":"8","author":"Martinez","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003382","article-title":"Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner","volume":"10","author":"Thakkar","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-sitc2022.0425","article-title":"425\u2005KVA12.1: an anti-VISTA monoclonal antibody with strong single agent anti-tumor activity and no evidence of cytokine mediated toxicity","volume":"10","author":"Guillaudeux","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1311658","article-title":"A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors","volume":"14","author":"Iadonato","year":"2023","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1038\/s41467-024-47256-x","article-title":"VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response","volume":"15","author":"Thisted","year":"2024","journal-title":"Nat Commun"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1389201003379059","article-title":"Rituximab: the first monoclonal antibody approved for the treatment of lymphoma","volume":"1","author":"Grillo-Lopez","year":"2000","journal-title":"Curr Pharm Bio\/Technol"},{"key":"B118","volume-title":"New drug approvals - March 2022","year":"2022"},{"key":"B119","volume-title":"Biosimilar approved","year":"2025"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-022-00100-4","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J BioMed Sci"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730666","article-title":"Toripalimab: the first domestic anti-tumor PD-1 antibody in China","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40199-023-00485-9","article-title":"Cost minimization analysis of subcutaneous trastuzumab versus intravenous biosimilar trastuzumab: policy recommendations for breast cancer treatment in Malaysia","volume":"32","author":"Heng","year":"2024","journal-title":"Daru"},{"key":"B124","doi-asserted-by":"publisher","first-page":"10781552221104773","DOI":"10.1177\/10781552221104773","article-title":"Perspectives toward biosimilars among oncologists: A Malaysian survey","volume":"32","author":"Chong","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"B125","volume-title":"Clinical practice guidelines: management of breast cancer","year":"2019"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"372","author":"Brinkmann","year":"2021","journal-title":"Science"},{"key":"B128","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B129","unstructured":"Akeso's cadonilimab receives second indication approval from NMPA for first-line treatment of gastric\/GEJ cancer in all-comers population\n          \n          2024"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1611696","article-title":"Real-world data of cadonilimab in recurrent or metastatic cervical cancer in China: a multicentric study","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B132","article-title":"CT006 Cadonilimab plus chemotherapy versus chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma (COMPASSION-15): a randomized, double-blind, phase 3 trial","author":"Ji","year":"2024"},{"key":"B133","unstructured":"Akeso's PD-1\/CTLA-4 bispecific antibody cadonilimab approved for first-line treatment of cervical cancer in all-comer populations\u2014Third approved indication for cadonilimab\n          \n          2025"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"key":"B135","unstructured":"Ivonescimab receives NMPA approval for first-line treatment of PD-L1-positive NSCLC, based on breakthrough head to head phase III trial demonstrating superior efficacy over pembrolizumab\n          \n          2025"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02073-w","article-title":"Ivonescimab: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-24-0708","article-title":"The journey of antibody-drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B139","volume-title":"Important information for LUMOXITI (mexetumomab pasudotox-tdfk) for injection, for intravenous use - permanent withdrawal of LUMOXITI from the US market","year":"2022"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1787148","article-title":"Clinical applications of antibody-drug conjugates in advanced non-small cell lung cancer","volume":"17","author":"Guo","year":"2026","journal-title":"Front Immunol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol Cancer"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16432","article-title":"Safety and effectiveness of nivolumab in Japanese patients with Malignant melanoma: Final analysis of a post-marketing surveillance","volume":"49","author":"Uhara","year":"2022","journal-title":"J Dermatol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1177\/10732748221111296","article-title":"Tislelizumab: A modified anti-tumor programmed death receptor 1 antibody","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Control"},{"key":"B144","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41392-022-01213-6","article-title":"Phase I study of camrelizumab in patients with advanced solid tumors","volume":"8","author":"Ma","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01286-z","article-title":"Tislelizumab: first approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"B146","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ccell.2020.12.005","article-title":"The landscape of cell and gene therapies for solid tumors","volume":"39","author":"Wang","year":"2021","journal-title":"Cancer Cell"},{"key":"B147","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B148","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"key":"B149","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11033-023-09096-8","article-title":"Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy","volume":"51","author":"Zafar","year":"2024","journal-title":"Mol Biol Rep"},{"key":"B150","unstructured":"2021"},{"key":"B151","volume-title":"Merck's Keytruda gets Singapore HSA nod, aiding regional prospects [press release]","author":"Lane","year":"2015"},{"key":"B152","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-024-01602-0","article-title":"Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China's responses to address secondary cancer risks of CAR-T therapy","volume":"17","author":"Tan","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.reth.2025.02.001","article-title":"Optimizing the commercial manufacturing of tisagenlecleucel for patients in Japan: A 4-year experiential journey","volume":"28","author":"Iwamoto","year":"2025","journal-title":"Regener Ther"},{"key":"B154","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/oxfordhb\/9780199777716.013.28","article-title":"A unique hub-and-spoke model to optimize patient management in lymphoma using novel CAR-T cell therapy in Southeast and South Asia","volume":"40","author":"Wei Inng Lim","year":"2022","journal-title":"Hematol Oncol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-023-00254-3","article-title":"Diversity in oncology clinical trials: Current landscape for industry-sponsored clinical trials in Asia","volume":"12","author":"Habr","year":"2024","journal-title":"Oncol Ther"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.4103\/picr.picr_109_18","article-title":"Clinical trials in Asia: A World Health Organization database study","volume":"10","author":"Ali","year":"2019","journal-title":"Perspect Clin Res"},{"key":"B157","unstructured":"Number of clinical trials by year, country, WHO region and income group (1999-2024)\n          \n          \n          2024"},{"key":"B158","doi-asserted-by":"publisher","first-page":"e14510\u2013e14510","DOI":"10.1200\/JCO.2022.40.16_suppl.e14510","article-title":"Clinical trial and translational research for cancer immunology in Asian countries: Understanding the new frontier","volume":"40","author":"Cruz Ordinario","year":"2022","journal-title":"J Clin Oncol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.31547\/bct-2023-023","article-title":"Challenges in global access to CAR-T cells: an Asian perspective","volume":"7","author":"Hwang","year":"2024","journal-title":"Blood Cell Ther"},{"key":"B160","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","article-title":"The clinical landscape of CAR NK cells","volume":"14","author":"Jorgensen","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.992232","article-title":"Preclinical and clinical studies of CAR-NK-cell therapies for Malignancies","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2025.04.064","article-title":"Dark NKnight rising: a current perspective on NK cell and CAR-NK cell therapy","volume":"27","author":"Caporale","year":"2025","journal-title":"Cytotherapy"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011278","article-title":"Asia's emergence in cancer immunotherapy: challenges and opportunities","volume":"13","author":"Li","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B164","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1186\/s12885-025-14026-x","article-title":"Artificial intelligence utilization in cancer screening program across ASEAN: a scoping review","volume":"25","author":"Tun","year":"2025","journal-title":"BMC Cancer"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02010","article-title":"Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non-small-cell lung cancer","volume":"40","author":"Park","year":"2022","journal-title":"J Clin Oncol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.2196\/71591","article-title":"Insights into the current and future state of AI adoption within health systems in Southeast Asia: Cross-sectional qualitative study","volume":"27","author":"Wibowo","year":"2025","journal-title":"J Med Internet Res"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1111\/odi.13892","article-title":"High referral accuracy for oral cancers and oral potentially Malignant disorders using telemedicine","volume":"29","author":"Haron","year":"2023","journal-title":"Oral Dis"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1089\/tmj.2018.0285","article-title":"m-Health for early detection of oral cancer in low- and middle-income countries","volume":"26","author":"Haron","year":"2020","journal-title":"Telemed J E Health"},{"key":"B169","unstructured":"Adam\n              A\n            \n          \n          AstraZeneca expands AI lung screening to public hospitals in Malaysia: Healthcare IT News\n          \n          2023"},{"key":"B170","unstructured":"APU and heydoc health advance AI-driven telemedicine for rural healthcare in Malaysia asia pacific university 2026\n          \n          2026"},{"key":"B171","article-title":"Economic Planning Unit, Prime Minister\u2019s Department, Malaysia","volume-title":"Malaysia Digital Economy Blueprint","year":"2021"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1177\/20552076251353279","article-title":"The evolution of healthcare digitalisation policies in Malaysia: A four-decade narrative review (1985-2025)","volume":"11","author":"Naim","year":"2025","journal-title":"Digit Health"},{"key":"B173","volume-title":"Artificial intelligence roadmap 2021-2025","author":"Alias","year":"2023"},{"key":"B174","unstructured":"Futurise - shaping Malaysia's regulatory innovation landscape Digital News Asia\n          \n          \n            \n              Baharudin\n              RS\n            \n          \n          \n          2024"},{"key":"B175","unstructured":"Ministry of Science, Technology and Innovation (MOSTI)\n          National Technology and Innovation Sandbox (NTS): Progress Report 2020-2021\n          \n          2020"},{"key":"B176","unstructured":"Said\n              F\n            \n          \n          Empowering Innovation: Strategic Insights into Malaysia's Sandbox Initiatives Tech For Good Institute\n          \n          2024"},{"key":"B177","article-title":"AI","volume-title":"sandboz launch with NVIDIA","year":"2024"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2435598","article-title":"Global research trends on biomarkers for cancer immunotherapy: Visualization and bibliometric analysis","volume":"21","author":"Qiao","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.387","article-title":"Progresses in biomarkers for cancer immunotherapy","volume":"4","author":"Lin","year":"2023","journal-title":"MedComm (2020)"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.029","article-title":"AI-driven predictive biomarker discovery with contrastive learning to improve clinical trial outcomes","volume":"43","author":"Arango-Argoty","year":"2025","journal-title":"Cancer Cell"},{"key":"B182","unstructured":"SG Ramps Up Cancer Fight with S$50 million in National Grant Funding for Precision Oncology\n          \n          2024"},{"key":"B183","doi-asserted-by":"publisher","first-page":"574","DOI":"10.21203\/rs.3.rs-3825334\/v1","article-title":"Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09","volume":"24","author":"Kim","year":"2024","journal-title":"BMC Cancer"},{"key":"B184","unstructured":"Precision medicine\n          \n          2019"},{"key":"B185","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21315\/mjms2021.28.3.1","article-title":"Precision medicine: Making it happen for Malaysia","volume":"28","author":"Jamal","year":"2021","journal-title":"Malays J Med Sci"},{"key":"B186","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12919-022-00237-8","article-title":"6th International Conference on Molecular Diagnostics and Biomarker Discovery (MDBD 2022): Building Resilience in Biomedical Research: Penang, Malaysia. 11-13 October 2022","volume":"16","year":"2022","journal-title":"BMC Proc"},{"key":"B187","volume-title":"Biomarker discovery in lung cancer-Malaysia","year":"2024"},{"key":"B188","doi-asserted-by":"publisher","first-page":"324","DOI":"10.21037\/atm-22-988","article-title":"Utilization of genetic biomarkers testing and its associated factors in advanced colorectal cancer patients in China: a nationwide multicenter clinical epidemiological study","volume":"10","author":"Zhang","year":"2022","journal-title":"Ann Transl Med"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100907","article-title":"Early lung cancer diagnostic biomarker discovery by machine learning methods","volume":"14","author":"Xie","year":"2021","journal-title":"Transl Oncol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008655","article-title":"SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials","volume":"12","author":"Lotze","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010928","article-title":"Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols","volume":"13","author":"Cottrell","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000036770","article-title":"PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer","volume":"103","author":"Guo","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14442","article-title":"Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country","volume":"13","author":"How","year":"2022","journal-title":"Thorac Cancer"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2024.0040","article-title":"Prevalence of programmed death-ligand 1 positivity using SP142 in patients with advanced stage triple-negative breast cancer in Malaysia: A cross-sectional study","volume":"27","author":"Rajadurai","year":"2024","journal-title":"J Breast Cancer"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2014.15.7.3287","article-title":"Colorectal carcinoma in Malaysians: DNA mismatch repair pattern in a multiethnic population","volume":"15","author":"Cheah","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2011.03.005","article-title":"Microsatellite instability and loss of heterozygosity in oral squamous cell carcinoma in Malaysian population","volume":"47","author":"Ashazila","year":"2011","journal-title":"Oral Oncol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.08.022","article-title":"Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors","volume":"40","author":"Nassar","year":"2022","journal-title":"Cancer Cell"},{"key":"B198","doi-asserted-by":"publisher","first-page":"6433","DOI":"10.1038\/s41467-020-20173-5","article-title":"The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences","volume":"11","author":"Pan","year":"2020","journal-title":"Nat Commun"},{"key":"B199","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13058-024-01826-5","article-title":"Clustering of HR + \/HER2- breast cancer in an Asian cohort is driven by immune phenotypes","volume":"26","author":"Pan","year":"2024","journal-title":"Breast Cancer Res"},{"key":"B200","doi-asserted-by":"publisher","first-page":"21723","DOI":"10.1038\/s41598-025-06983-x","article-title":"Characterisation of gut microbiota in Malaysian cancer patients using V3-V4 region of 16S rRNA gene sequencing","volume":"15","author":"Sidi Omar","year":"2025","journal-title":"Sci Rep"},{"key":"B201","unstructured":"Announces acceptance of its new drug application for ciltacabtagene autoleucel (cilta-cel) in China\n          \n          2023"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"B203","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s41649-021-00171-5","article-title":"Current status and future challenges of biobank research in Malaysia","volume":"13","author":"Amin","year":"2021","journal-title":"Asian Bioeth Rev"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00592-6","article-title":"Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial","volume":"14","author":"Huang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B205","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_190_20","article-title":"Robo1-specific chimeric antigen receptor natural killer cell therapy for pancreatic ductal adenocarcinoma with liver metastasis","volume":"16","author":"Li","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"B207","article-title":"Phase 1 study of GCC2005, an allogeneic CD5-directed CAR-NK therapy, for patients with Relapsed\/Refractory NK\/T-cell malignancies","volume-title":"Blood","author":"Kim","year":"2025"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-0715-0_2","article-title":"A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2","volume":"100","author":"Rosenberg","year":"1986","journal-title":"Surgery"},{"key":"B209","unstructured":"FDA approves first cellular therapy for solid tumor cancer\n          \n          \n            \n              Phillips\n              C\n            \n          \n          National Cancer Institute (NCI) Cancer Currents Blog\n          \n          2024"},{"key":"B210","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s00262-024-03793-4","article-title":"Recent clinical researches and technological development in TIL therapy","volume":"73","author":"Matsueda","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-1922","article-title":"Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future","volume":"29","author":"Betof Warner","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J Clin Oncol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-1171","article-title":"Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma","volume":"27","author":"Seitter","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-1879","article-title":"Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B217","article-title":"Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma","volume":"12","author":"Pillai","year":"2022","journal-title":"Am J Cancer Res"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00044","article-title":"Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"8","author":"Mullinax","year":"2018","journal-title":"Front Oncol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.tps9607","article-title":"A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma","volume":"41","author":"Olson","year":"2023","journal-title":"J Clin Oncol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.492","article-title":"Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naive patients with advanced cancers","volume":"9","author":"O'Malley","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B221","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.12.417","article-title":"Tumor infiltrating lymphocytes (TILs) therapy \u2013 report of the first TILs therapy infusion from India, for a patient of malignant melanoma","volume-title":"Transplant Cell Ther","author":"Cyriac","year":"2024"},{"key":"B222","unstructured":"Two cancer surgeons each receive $6m research award to study cancers prevalent in Singapore\n          \n          \n            \n              Lee\n              LY\n            \n          \n          The Straits Times\n          \n          2026"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.70346","article-title":"Phenotypic analysis of 26 cultured TILs derived from Japanese melanoma tissues","author":"Oguma","year":"2026","journal-title":"J Dermatol"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15009","article-title":"Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors","volume":"112","author":"Hirai","year":"2021","journal-title":"Cancer Sci"},{"key":"B225","unstructured":"REPROCELL\n          Cellular immunotherapy for cervical cancer: tumor infiltrating lymphocyte (TIL) therapy"},{"key":"B226","unstructured":"A phase 2 study using short-term cultured anti-tumor autologous lymphocytes following a nonmyeloablative conditioning and low-dose interleukin-2 treatment in patients with recurrent, metastatic, or persistent cervical cancer (TILCC trial)"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103261","article-title":"Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancer","volume":"84","author":"Tay-Teo","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B228","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41571-022-00700-7","article-title":"Barriers in access to oncology drugs - a global crisis","volume":"20","author":"Barrios","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B229","unstructured":"Mohamad Selamat\n              E\n            \n            \n              Abdul Hadi\n              SR\n            \n            \n              Yusof\n              N\n            \n            \n              Halim\n              H\n            \n            \n              Mohd Rashidi\n              NF\n            \n            \n              Periana Kovindear\n              A\n            \n          \n          Malaysia National Health Accounts (MNHA) Section, Planning Division, Ministry of Health Malaysia\n          Malaysia National Health Accounts: 2011\u20132023\n          \n          2025"},{"key":"B230","article-title":"Cell interactions in the induction of tolerance: the role of thymic lymphocytes","volume":"18","author":"Gershon","year":"1970","journal-title":"Immunology"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70290","article-title":"The cancer burden in Sarawak, Malaysia: Sarawak cancer report","volume":"8","author":"Tan","year":"2025","journal-title":"Health Sci Rep"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.02.017","article-title":"Asian diversity in human immune cells","volume":"188","author":"Kock","year":"2025","journal-title":"Cell"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.3390\/biology13050307","article-title":"Current landscape of cancer immunotherapy: harnessing the immune arsenal to overcome immune evasion","volume":"13","author":"Mitra","year":"2024","journal-title":"Biol (Basel)"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103647","article-title":"Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer","volume":"9","author":"Chen","year":"2024","journal-title":"ESMO Open"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1002\/pon.70139","article-title":"Facilitators and barriers to cancer screening participation across Southeastic Asia: a scoping review","volume":"34","author":"Higgins","year":"2025","journal-title":"Psychooncology"},{"key":"B236","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/s12889-020-08581-0","article-title":"Cancer symptom and risk factor awareness in Malaysia: findings from a nationwide cross-sectional study","volume":"20","author":"Schliemann","year":"2020","journal-title":"BMC Public Health"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2020.101882","article-title":"Anticipated delay in help-seeking for cancer symptoms: findings from a nationwide study of Malaysian adults","volume":"71","author":"Schliemann","year":"2021","journal-title":"Cancer Epidemiol"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036503","article-title":"Impact of a mass media campaign on breast cancer symptoms awareness and screening uptake in Malaysia: findings from a quasi-experimental study","volume":"10","author":"Schliemann","year":"2020","journal-title":"BMJ Open"},{"key":"B239","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12913-023-10327-8","article-title":"Cancer screening programs in South-east Asia and Western Pacific","volume":"24","author":"Wee","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph182312293","article-title":"Breast cancer screening in semi-rural Malaysia: utilisation and barriers","volume":"18","author":"Mohan","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B241","doi-asserted-by":"publisher","first-page":"114361","DOI":"10.1016\/j.ejpb.2024.114361","article-title":"Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and India","volume":"201","author":"S","year":"2024","journal-title":"Eur J Pharm Biopharm"},{"key":"B242","volume-title":"Drug registration guidance document (DRGD) third edition, fourth revision january 2023 (Appendix 14)","year":"2023"},{"key":"B243","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12961-023-01063-w","article-title":"Development of the national policy for quality in healthcare for Malaysia","volume":"21","author":"Awang","year":"2023","journal-title":"Health Res Policy Syst"},{"key":"B244","unstructured":"Ismail\n              H\n            \n            \n              Lee\n              HNE\n            \n          \n          Hospital Management Unit, Medical Development Division, Ministry of Health Malaysia\n          Pelan Strategik Kementerian Kesihatan Malaysia 2021\u20132025\n          \n          2021"},{"key":"B245","article-title":"Harmonization of regulatory requirements for registration of drug products in ASEAN nations","volume":"9","author":"Reddy","year":"2018","journal-title":"Res J Pharm Biol Che"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0510-9","article-title":"A survey on pharmacovigilance activities in ASEAN and selected non-ASEAN countries, and the use of quantitative signal detection algorithms","volume":"40","author":"Chan","year":"2017","journal-title":"Drug Saf"},{"key":"B247","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12916-024-03637-z","article-title":"Post-marketing surveillance framework of cell and gene therapy products in the European Union, the United States, Japan, South Korea and China: a comparative study","volume":"22","author":"Cai","year":"2024","journal-title":"BMC Med"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.35629\/4494-100225952601","article-title":"A report on-from clinical trials to post marketing surveillance: the evaluation of safety data generation in pharmacovigilance","volume":"10","author":"Wasiullah","year":"2025","journal-title":"Int J Pharm Res Appl"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1200\/go.23.00040","article-title":"Operational challenges of an Asia-Pacific academic oncology clinical trial","volume":"9","author":"Day","year":"2023","journal-title":"JCO Glob Oncol"},{"key":"B250","volume-title":"International collaboration and international regulatory harmonization can combat cancer: The common enemy of humanity","year":""},{"key":"B251","volume-title":"Advancing Global Health Equity","author":"Li","year":"2023"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2019.1601060","article-title":"Government pharmaceutical pricing strategies in the Asia-Pacific region: An overview","volume":"7","author":"Verghese","year":"2019","journal-title":"J Mark Access Health Policy"},{"key":"B253","doi-asserted-by":"publisher","first-page":"16","DOI":"10.12688\/gatesopenres.13110.3","article-title":"Value-based tiered pricing for universal health coverage: An idea worth revisiting","volume":"4","author":"Chalkidou","year":"2020","journal-title":"Gates Open Res"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s420890","article-title":"Challenges and strategies for improving access to cancer drugs in Malaysia: Summary of opinions expressed at the 2nd MACR International Scientific Conference 2022","volume":"15","author":"Tan","year":"2023","journal-title":"Cancer Manag Res"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2019.03.003","article-title":"Health technology assessment and its use in drug policy in Malaysia","volume":"18","author":"Shafie","year":"2019","journal-title":"Value Health Reg Issues"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1847284\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:43:46Z","timestamp":1786607026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1847284\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":255,"alternative-id":["10.3389\/fonc.2026.1847284"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1847284","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"1847284"}}